Collegium provides 2023 guidance: rev $565-580M, adj EBITDA $355-370M, $100M buyback

COLLEGIUM PHARMACEUTICAL, INC

Product revenue net expected $565-580M for 2023, up from ~$460M in 2022.
Adjusted EBITDA $355-370M, growing >4x rate of adjusted operating expenses ($135-145M).
Board authorized $100M share repurchase program through December 31, 2023.
Xtampza ER gross-to-net expected 61-63% in 2023, down from >65% previously.
Federal Circuit upheld Belbuca patents, blocking Alvogen generic entry until 2032.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.